Dubai Investments PJSC

Globalpharma, a leading pharmaceutical manufacturer in the UAE, has signed four strategic Memorandums of Understanding (MoUs) during the Make it in the Emirates Forum 2025. These agreements aim to strengthen the UAE's position as a hub for pharmaceutical innovation and advanced healthcare manufacturing. The MoUs involve collaborations with PharmaPrimes Laboratories (Jordan), Nerhadou International (Egypt), Aora Health (Spain), and BioSyent Pharma Inc. (Canada), focusing on technology transfer, product licensing, supply, and local manufacturing. These partnerships align with the UAE's industrial strategy to boost domestic production, reduce import dependence, and enhance access to next-generation healthcare solutions. The agreements reflect the UAE's commitment to empowering local industry, accelerating innovation, and establishing the country as a global hub for high-quality healthcare solutions. Specific collaborations include PharmaPrimes Laboratories working on biosimilar drug capabilities in the UAE and Nerhadou International introducing a range of nutraceutical and OTC products tailored to regional health needs.

Emirates Extrusion Factory (EEF), a subsidiary of Dubai Investments, has partnered with UCS Green Solutions to introduce the UAE's first zero-waste Green Curtain Wall System. This exclusive agreement, announced at the 'Make it in the Emirates' forum, designates EEF as the sole manufacturer of UCS's innovative façade system, which aims to eliminate material waste during installation. This collaboration supports the UAE's sustainability goals and represents a significant advancement in the regional construction industry. The Green Curtain Wall System combines aesthetics with environmental performance, reflecting a shift towards circular manufacturing. The partnership is aligned with the UAE's long-term industrial and environmental objectives, including Operation 300bn and the Net Zero by 2050 initiative, addressing the construction sector's need to reduce its environmental impact.

Dubai Investments PJSC reported a 52% increase in profit before tax for Q1 2025, reaching AED 185 million, up from AED 122 million in the same period last year. This growth was mainly due to higher rental income and stable occupancy in its property segment. The company's total income rose to AED 823 million, and total assets increased to AED 22.27 billion as of March 31, 2025. Vice Chairman and CEO Khalid Bin Kalban attributed the strong performance to the company's strategic vision and diversified portfolio, particularly in the real estate sector. Dubai Investments plans to continue expanding in real estate with projects like Danah Bay, Violet Tower, and Asayel Avenue. The company is also focusing on diversifying its income streams and exploring opportunities in other sectors to ensure sustainable growth.

Dubai Investments PJSC, along with its subsidiaries, has released its condensed consolidated interim financial statements for the three-month period ending on March 31, 2025.

Dubai Investments, a diversified investment company listed on the Dubai Financial Market, released its 2024 ESG Report titled "Resilient Futures – Advancing Sustainability Through Innovation and Collaboration." The report showcases progress in clean energy, operational efficiency, workforce development, and community initiatives across its 12 subsidiaries. It aligns with international and national standards such as GRI, DFM ESG Indicators, and UAE’s sustainability vision. The company emphasizes strong corporate governance, ethical conduct, and transparency. Key achievements include a 1.2 MW rooftop solar system at Ritaj community, energy efficiency improvements at Emirates Float Glass, and 100% aluminum scrap reuse at Emirates Extrusion Factory. Water conservation efforts and human capital development, with extensive employee training and career development, were also highlighted. Community engagement initiatives included the Green Run and school supply campaigns.

Dubai Investments announced an 18% cash dividend, totaling AED 765.36 million, for the financial year ending December 31, 2024, which was approved at the 29th Annual General Meeting on April 16, 2025. The company reported a net profit before tax of AED 1.3 billion for 2024, a 21% increase from the previous year, reflecting its strategic growth and operational excellence. The AGM also approved a new Dividend Distribution Policy. Dubai Investments, established in 1995, is a UAE-based multi-asset investment group with a diverse portfolio in sectors such as real estate, manufacturing, and healthcare, and aims to generate sustainable financial returns and drive growth through strategic investments.

Globalpharma, a leading pharmaceutical manufacturer in the UAE and a subsidiary of Dubai Investments PJSC, has partnered with India's ZIM Laboratories to introduce EU-certified Oral Dispersible Film (ODF) technology to its product range. This technology, which meets high international quality and safety standards, was announced at the AIM Congress 2025 in Dubai. The collaboration aims to enhance the UAE's role in global pharmaceutical innovation and improve healthcare solutions. The agreement was signed by key representatives from both companies and witnessed by notable officials. Globalpharma's leaders highlighted the UAE's growing influence in pharmaceutical manufacturing and discussed industry trends at the congress. The partnership with ZIM Labs is seen as a significant step in advancing patient-centric treatment options and strengthening the region's pharmaceutical capabilities. ODFs are thin, fast-dissolving strips that improve medication compliance, especially for children, the elderly, and those with swallowing difficulties. Globalpharma plans to produce these innovative treatments locally, setting a new standard for pharmaceutical manufacturing in the region.

The disclosure clarifies the process for shareholders to delegate someone to attend the General Assembly on their behalf. Shareholders can delegate individuals who are not board members, company staff, or employees of a securities brokerage company. The delegated person can represent multiple shareholders but cannot exceed 5% of the company's issued capital. Legal representatives must represent those lacking legal capacity. The shareholder's signature on the power of attorney must be approved by specific entities such as a Notary Public, Chamber of Commerce, a bank where the shareholder has an account, licensed financial markets, or any licensed notarial entity in the UAE. The proxy form should include the shareholder's name, contact number, and the approving authority. For further inquiries, contact details are provided.